Table 3.

Summary of Studies in Patients With TGCT in Hand, Hip, Ankle, and Foot

Study (No. of pts)	Study Design (Tx period) LOE	Dx, F/U	Tx	Efficacya	Complicationsa
Hand
Koutserimpas et al35 (n = 36)	Retrospective cohort (2005-2015) LOE: III	GCTTS F/U: 21b mo	Radical tumor resection	Recurrence: 11%	Postop: 11%
Hip
Tibbo et al36(n = 25)	Retrospective cohort (1971-2013) LOE: III	Diffuse PVNS F/U: 10b yr	THA	5-yr DFS: 100% 10-yr DFS: 100% 20-yr DFS: 100% Recurrence: 4%	Postop: 76% 5-yr SFR: 83% 10-yr SFR: 63%
Foot and ankle
Korim et al37 (n = 30)	Retrospective cohort (2000-2010) LOE: III	DTGCT or localized PVNS F/U: 4b yr	Open Sv	Recurrence: PVNS group (none); DTGCT group (12%)	NR

DFS = disease-free survival, DTGCT = diffuse-type giant cell tumor, Dx = diagnosis, F/U = follow-up, GCTTS = giant cell tumor of tendon sheath, LOE = level of evidence, NR = not reported, postop = postoperative, pts = patients, PVNS = pigmented villonodular synovitis, SFR = survivorship free from any revision, Sv = synovectomy, TGCT = tenosynovial giant cell tumor, THA = total hip arthroscopy, Tx = treatment

^aPercentage of patients.

^bMean follow-up.